{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:06:12Z","timestamp":1779199572057,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.labinv.2026.106121","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:58:12Z","timestamp":1773457092000},"page":"106121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Programmed Death Ligand-1 Testing in Triple-Negative Breast Cancer: National Practice and Interlaboratory Variation in the Netherlands"],"prefix":"10.1016","volume":"106","author":[{"given":"Mirte","family":"Dekker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike Anna","family":"Hempenius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Kruchten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel A.T.M.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert G.","family":"Siebers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-1506","authenticated-orcid":false,"given":"Bert","family":"van der Vegt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.labinv.2026.106121_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0459","article-title":"Breast cancer: presentation, investigation and management","volume":"83","author":"Katsura","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"issue":"2","key":"10.1016\/j.labinv.2026.106121_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.labinv.2026.106121_bib4","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.labinv.2026.106121_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.labinv.2026.106121_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/oncolo\/oyad025","article-title":"Variable landscape of PD-L1 expression in breast carcinoma as detected by the DAKO 22C3 immunohistochemistry assay","volume":"28","author":"Danziger","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.labinv.2026.106121_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jcp-2022-208637","article-title":"Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens","volume":"77","author":"Noske","year":"2023","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.labinv.2026.106121_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.labinv.2026.106121_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.labinv.2026.106121_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.labinv.2026.106121_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000510812","article-title":"Understanding PD-L1 testing in breast cancer: a practical approach","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"4","key":"10.1016\/j.labinv.2026.106121_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.labinv.2026.106121_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2021.07.012","article-title":"Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients","volume":"159","author":"Koomen","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.labinv.2026.106121_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/his.15184","article-title":"Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands\u2014a nationwide evaluation study","volume":"85","author":"Hempenius","year":"2024","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.labinv.2026.106121_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.32074\/1591-951X-836","article-title":"A practical approach for PD-L1 evaluation in gastroesophageal cancer","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"issue":"2","key":"10.1016\/j.labinv.2026.106121_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.labinv.2026.106121_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.labinv.2026.106121_bib18","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"issue":"8","key":"10.1016\/j.labinv.2026.106121_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/sim.1970","article-title":"Funnel plots for comparing institutional performance","volume":"24","author":"Spiegelhalter","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.labinv.2026.106121_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/tbcr-24-15","article-title":"Expert consensus on the clinical application of immunotherapy in breast cancer: 2024","volume":"5","author":"Wang","year":"2024","journal-title":"Transl Breast Cancer Res"},{"issue":"18","key":"10.1016\/j.labinv.2026.106121_bib21","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications from pathologist\u2019s perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2026.106121_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285764","article-title":"Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications","volume":"18","author":"Vainer","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.labinv.2026.106121_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00428-019-02595-9","article-title":"Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen","volume":"475","author":"van Seijen","year":"2019","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.labinv.2026.106121_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antib10030024","article-title":"Higher PD-L1 immunohistochemical detection signal in frozen compared to matched paraffin-embedded formalin-fixed tissues","volume":"10","author":"Ghebeh","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.labinv.2026.106121_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00428-019-02613-w","article-title":"Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones","volume":"475","author":"Forest","year":"2019","journal-title":"Virchows Arch"},{"issue":"02","key":"10.1016\/j.labinv.2026.106121_bib26","first-page":"2","article-title":"Pre-analytical challenges during RAS testing: tissue quality and the estimation of neoplastic cell percentage","volume":"05","author":"Dufraing","year":"2019","journal-title":"Biomark J"},{"issue":"10","key":"10.1016\/j.labinv.2026.106121_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.1666","article-title":"P2.09-17 real-world concordance across pathologists for PD-L1 scoring in non-small cell lung cancer: results from a large nationwide initiative","volume":"14","author":"Adam","year":"2019","journal-title":"J Thoracic Oncol"},{"issue":"11","key":"10.1016\/j.labinv.2026.106121_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.23267","article-title":"Evaluation of the use of combined artificial intelligence and pathologist assessment to review and grade prostate biopsies","volume":"3","author":"Steiner","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.labinv.2026.106121_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/his.15205","article-title":"Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: a multi-institutional ring study","volume":"85","author":"Li","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.labinv.2026.106121_bib30","article-title":"Clinical evaluation of an automated pan-organ combined PD-L1 scoring using artificial intelligence on immunostained whole-slide images","volume":"10","author":"Bossard","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.labinv.2026.106121_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis","volume":"99","author":"Boman","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.labinv.2026.106121_bib32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:08:06Z","timestamp":1779196086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683726000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0023683726000516"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106121","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed Death Ligand-1 Testing in Triple-Negative Breast Cancer: National Practice and Interlaboratory Variation in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"106121"}}